Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej W Ostrowi Mazowieckiej
- Address
- Ul. Stanislawa Duboisa 68, 07-300 Ostrow Mazowiecka, Poland
Diseases [C] - Bacterial Infections and Mycoses [C01]
Research at Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej W Ostrowi Mazowieckiej includes work in bacterial infections, with a focus on preventing post-surgical incisional infection after abdominal surgery. The studies are designed to evaluate whether adding a new anti-infective approach to standard care can improve infection prevention and support patient safety.
- Preventing surgical site infection after abdominal procedures
- Assessing the effectiveness of an anti-infective therapy alongside standard care
- Evaluating safety in the setting of postoperative infection prevention
This area reflects practical clinical research aimed at lowering the risk of infection in surgical patients and improving recovery outcomes.
Diseases [C] - Cardiovascular Diseases [C14]
The site is also active in cardiovascular disease research, especially hypertension and acute myocardial infarction including both ST-elevation and non-ST-elevation heart attacks. These trials are focused on improving blood pressure control and testing whether a new anti-inflammatory treatment can reduce serious heart-related events after a heart attack.
- Improving control of difficult-to-treat hypertension
- Evaluating treatment strategies for uncontrolled blood pressure
- Testing a new approach to reduce major adverse cardiovascular events after acute myocardial infarction
The cardiovascular studies combine everyday clinical concerns, such as blood pressure management, with research into newer therapies that may help protect patients after a major cardiac event.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Agencja Badań Medycznych1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej W Ostrowi Mazowieckiej
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction. | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlodipine | 1 | Unknown | 2023-10-24 | 2023-10-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.